spacer
home > epc > autumn 2002 > comparison of the regulatory ames test with the sos/umu assay as part of lead optimisation screening
PUBLICATIONS
European Pharmaceutical Contractor

Comparison of the Regulatory Ames Test with the SOS/umu Assay as Part of Lead Optimisation Screening

In our experience, regulatory genetic toxicology testing consistently produces 20-25 per cent in vitro positive results each year (Ames, cytogenetics and mammalian cell mutation). For the customers concerned, this means, at best, significant delays while further testing is carried out using more precious compound. At worst the pharmaceutical will fail further down the development pipeline.

Either way a positive genetic toxicology result leads to considerable cost and delay. The problem is even greater when using the 'fast-track, early into human' approach preferred by some customers when the toxicology study package has been 'compressed' to save time. A significant failure will bring down a whole programme. To aid screening for potential genotoxins, we assessed the performance of the SOS/umu assay, carried out in microwell plates, when compared to the regulatory Ames test performed to OECD guidelines.

Materials and Methods

The SOS/umu assay, performed in microwell plates, has the advantage of being sensitive to a wide range of genotoxins and has been shown to correlate well with the Ames test.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

Banner of CRS on Samedan
spacer
By Jon Kitching, Department of Experimental Biology at Huntingdon Life Sciences

Jon Kitching heads up the Molecular Toxicology Group within the Experimental Biology Department at Huntingdon Life Sciences. With a dual honours degree in Biochemistry and Microbiology, Jon previously worked in genetic toxicology for 12 years.

spacer
Jon Kitching
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

World Vaccine Congress

10-12 April 2012, Gaylord National Hotel and Convention Center, Washington, US

The 12th annual World Vaccine Congress Washington brings new scientific and business critical debate, discussion and solutions from the true global pioneers shaping vaccine R&D.
More info >>

 
News and Press Releases

Kallik’s new approach to asset management delivers long term artwork automisation

Marketing and compliance departments can now have greater control over their assets –from logos and images to labelling copy – and a roadmap to automated artwork generation, thanks to Kallik’s online Asset Repository. It is the most cost-effective way to lay the foundation for future automisation of the artwork and labelling generation. The practice of centralising the content in a web-based asset library and reusing those assets across all marketing and trade communications is saving businesses thousands, if not millions, of pounds.
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.